Elicio Therapeutics Inc.
(NASDAQ:ELTX) stock is trading lower on Monday after disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional treatment.
Elicio Therapeutics Misses Primary Endpoint But Highlights Early Benefit Signals While the trial did not achieve its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population, the company pointed to early treatment benefits and subgroup findings that are shaping its planned Phase 3 program.
The randomized study evaluated ELI-002 7P as an adjuvant treatment in patients with mKRAS-driven PDAC.
According to the company, landmark analyses conducted during active treatment showed an approximately 14% absolute improvement in DFS at both three and six months compared with observation.
